Mendes, Augusto J. http://orcid.org/0000-0002-9497-0707
Ribaldi, Federica
Lathuiliere, Aurelien
Ashton, Nicholas J.
Janelidze, Shorena
Zetterberg, Henrik
Scheffler, Max
Assal, Frédéric
Garibotto, Valentina
Blennow, Kaj
Hansson, Oskar
Frisoni, Giovanni B.
Funding for this research was provided by:
Horizon 2020 Framework Programme (667375)
Innovative Medicines Initiative (115736, 115952)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (320030_182772, 320030_169876, 320030_182772, 320030_182772, 320030_169876, 320030_185028, IZSEZ0_188355)
Velux Stiftung (1123)
Vetenskapsrådet (2022-01018, 2019-02397, 2022-00775)
HORIZON EUROPE Framework Programme (101053962, 860197)
Statens institutionsstyrelse (ALFGBG-71320)
Alzheimer's Drug Discovery Foundation (201809-2016862)
EU Joint Programme – Neurodegenerative Disease Research (JPND2021-00694)
UK Dementia Research Institute (UKDRI-1003)
Alzheimer's Association (SG-23-1061717)
Knut och Alice Wallenbergs Stiftelse (2017-0383)
University of Geneva
Article History
Received: 27 October 2023
Revised: 1 December 2023
Accepted: 3 December 2023
First Online: 9 January 2024
Declarations
:
: GBF has received unrestricted grants and support for event organization from ROCHE Pharmaceuticals; OM Pharma; EISAI Pharmaceuticals; Biogen Pharmaceuticals. VG received grants and speaker fees through her institution from Siemens Healthineers, GE Healthcare, Novo Nordisk and Janssen. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). OH has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. The other authors have nothing to disclose.